Prenatal exposure to serotonin reuptake inhibitors: a case report
© Marsella et al; licensee BioMed Central Ltd. 2010
Received: 7 July 2009
Accepted: 19 March 2010
Published: 19 March 2010
Two premature twins (33 weeks gestation) were born to a woman who had used paroxetine during pregnancy for an anxiety-depression disorder. They were admitted to the NICU, where they showed prolonged RDS, cardiovascular malformations, and facial dysmorphisms. Soon after birth, they also presented abnormal neurobehavioral and motor signs, which partially disappeared during the following weeks, although alterations of tone persisted even at discharge.
Selective serotonin reuptake inhibitor (SSRI) antidepressants are considered the primary treatments for depression and anxiety in pregnancy. Since intrauterine exposure to these drugs has been associated with poor neonatal adaptation, low birth weight, RDS, neurobehavioural symptoms, and potential teratogenic effects, further studies are needed to assess risks and mechanism of action of SSRIs. Meanwhile, it is advisable to evaluate for each patient the real risk/benefit ratio of continuing or suspending treatment during pregnancy.
Recent studies report that depression and anxiety disorders affect 12-18% and 1.5-5% of pregnant women, respectively . Selective serotonin reuptake inhibitor (fluoxetine, paroxetine, sertraline, etc) are considered the primary treatments for these disorders. In recent years several concerns have been raised about safety of some antidepressants during pregnancy.
In utero exposure to an SSRI has been associated with many neonatal symptoms, including respiratory distress, feeding difficulties, and a wide spectrum of neurological symptoms. A neonatal abstinence syndrome (NAS), resulting from exposure to SSRIs during pregnancy, may explain this clinical syndrome, characterized by central nervous system, gastrointestinal, autonomic and respiratory symptoms [2, 3]. In a cohort study, symptoms of NAS were present in 30% of exposed infants compared to none of the non-exposed control infants .
Furthermore, concerns regarding persistent pulmonary hypertension, teratogenic risks, and neonatal adaptation have also been raised. In particular, recent studies have indicated an increased prevalence of certain malformations, as omphalocele, craniosynostosis, and, more consistently, heart defects in newborns exposed to SSRIs in utero [4–8].
We here report details of two premature twins who, after in uteroexposure to SSRIs, presented symptoms compatible with the NAS and cardiovascular malformations.
We describe the case of two monozygotic, naturally conceived, twin girls born by cesarean section at 33 weeks gestation for premature rupture of membranes. Birth weights were 1420 (10-25th percentile) and 1250 g (<3rd percentile). Pregnancy was complicated by polihydroamnios and gestational diabetes. The mother had used paroxetine 5 and 20 mg/day for the first 2 months and last 3 weeks of gestation, respectively, for an anxiety-depression disorder. Ultrasound at 20 weeks gestation had shown right aortic arch in the first twin and a single umbilical artery in the second twin. Familial history was negative for congenital malformations or genetic disorders.
At birth both newborns presented cardiorespiratory depression and therefore were intubated and admitted to the NICU. They both received one dose of surfactant and, after extubation, were treated with CPAP through nasal prongs. Initial physical examination showed facial dysmorphisms, involving hypertelorism, proptosic eyes, hypoplasic nasal pyramide, wide antiverse nostrils. During the second day of life, the newborns also developed neurobehavioral and motor signs (hyperreactivity, irritability, jitteriness, hyperextension of the trunk and limbs with worsening of dyspnea during manipulations).
Echocardiograms in the first twin confirmed a right aortic arch and documented in both patients moderate valvular pulmonary stenosis and small ostium secundum. Cerebral ultrasound was normal in the first twin, while the second presented bilateral parietal hyperechogenic spots, which had disappeared at the first post-discharge ultrasound. Hemochrome, plasma electrolytes, glycemia, C-reactive protein, urine exam, and hemocolture excluded inflammatory/infectious and metabolic disorders. Kariotypes were normal in both twins.
In the following days they remained quite unstable and required n-CPAP for 34 and 28 days. Oxygen-therapy was continued till the 52nd and 55th day, respectively. Neurobehavioral and motor signs decreased slowly during the following weeks.
At discharge at 95 days the first twin presented hypertone at the lower limbs and the second a hypotonic syndrome with mild developmental delay in motor acquisitions; both had mild retractions, tachypnea and nasal congestion. Echocardiograms confirmed the presence of moderate valvular pulmonary stenosis.
At 6 months follow-up, the twins showed an adequate psychomotor development with resolution of neurobehavioral and respiratory symptoms.
Exposure to SSRIs has been associated with poor neonatal adaptation, low birth weight and a clinical picture characterized by neurobehavioral, gastrointestinal, respiratory and somatic symptoms . These findings have stimulated studies regarding their use in pregnancy and possible effects on fetus and newborn.
In literature, the most common neurobehavioral symptoms described in exposed newborns are: hypo or hypertonia, hyperreflexia, tremor, jitteriness, irritability, constant crying, agitation, spasms, seizures, and sleep disturbances. Higher rates of vomiting, diarrhoea, tachycardia, hypoglycemia, feeding difficulty, hyper or hypothermia and jaundice have also been described [9, 10].
As of November 2001, the FDA Adverse Event Reporting System contained 210 possible SRI-related neonatal behavioural syndrome cases, of which 57 met criteria for FDA case definition of NAS, and 37 seemed to be consistent with an acute neonatal toxicity syndrome .
In the withdrawal syndrome sleep disturbances, neurological, gastrointestinal, motor, and somatic changes are most frequent. Onset is between 2 days to 1 month from birth, and duration of symptoms is less than 2 weeks . The toxicity syndrome is characterized by symptoms which appear within the first hours after birth and usually present as neurobehavioral changes and respiratory difficulties (retractions, apnea/bradycardia, cyanosis, tachypnea and nasal congestion) .
While neurobehavioral, gastrointestinal and somatic manifestations are quite similar to those seen in adults assuming SSRIs, the respiratory problems, which may require prolonged hospitalization and ventilatory support, are not easily explained. Epidemiological and experimental data suggest an association between maternal use of SSRIs and the prevalence of persistent pulmonary hypertension of the newborn [12, 13]. However it is not easy to establish to which extent neonatal respiratory symptoms in exposed newborns are related to pulmonary hypertension.
In this case report we were not able to assess whether respiratory symptoms result either from a serotoninergic syndrome or simply from prematurity. The twins' gestational age does not explain such a prolonged RDS; on the other hand, there is evidence that preterms, born to mothers assuming SSRIs during pregnancy, are more susceptible to the effects of these drugs than term newborns. A recent retrospective cohort study demonstrated a higher prevalence of behavioral (100% vs 69.1%) and respiratory symptoms (66.7% vs 25.5%) and a longer median length of stay in preterm newborns compared to term newborns (14.5 vs 3.6 days) . Furthermore, as described in literature, the rate of prematurity itself was higher in the exposed group compared to a group of unexposed infants.
Our twins obviously had other reasons to be born prematurely (i.e. severe polihydroamnios), but we cannot exclude that paroxetine may have contributed.
The risk of malformations after antenatal exposure to SSRIs remains controversial . While early studies excluded major teratogenic effects of these drugs, in recent years associations between the exposure to specific SSRIs and selected malformations have been reported [5, 6, 15]. In particular an analysis of the association between specific birth defects and first trimester exposure to paroxetine showed a significant increase in right ventricular outflow tract obstruction . The clinical history of our twins characterized by an exposure of 7-8 weeks, during the first trimester, and presence of pulmonary stenosis is consistent with these previous findings. However, large, prospective studies are warranted to assess the teratogenic potential of SSRIs and answer this relevant safety question.
In order to prevent SSRI syndrome in newborns it has been suggested to taper or discontinue treatment 2 weeks prior to delivery, with resumption after birth . This approach is not always applicable because of unpredictability of birth timing and risk of recurrence of maternal disease, which may complicate pregnancy.
Another possibility could be continuation of maternal treatment with the SSRI during breastfeeding, which is not contraindicated, but requires close monitoring for neonatal symptoms . Monitoring serum levels of the drugs during breastfeeding is not possible in most hospitals, as in ours; therefore we believe that clinical observation is more important.
A therapeutic approach to newborns exposed to SSRI must include a quiet environment with minimal stimulation with lights, noises, or handling. Close cardiorespiratory monitoring and Finnegan Score assessment are recommended. Sedatives and anticonvulsants are seldomly required. Nordeng et al. described 3 paroxetine exposed newborns, who were treated with chlorpromazine, known to have sedative and antiserotoninergic effects. In one case treatment was interrupted because of side effects, while in the other two cases an almost complete resolution of symptoms was obtained .
Although concerns raised about possible neonatal risks associated with SSRI exposure during pregnancy are appropriate, the potential risks of depression and/or anxiety on maternal and neonatal well-being must not be underestimated. Indeed there is evidence that untreated psychiatric disorders may have unfavourable outcomes for both mother and newborn .
Information about safety profiles of SSRIs during pregnancy is limited and mostly due to post-marketing experience, but, since these drugs are the most widely used antidepressants in pregnancy, further studies are needed to assess risks and mechanisms of action. Currently it is advisable to use the lowest dosage possible, avoid multitherapy approaches and evaluate risk/benefit ratios of both continuing or suspending treatment during pregnancy in each single patient.
Written informed consent was obtained from the parents of the patients for publication of this case Report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- De las Cuevas C, Sanz EJ: Safety of selective serotonin reuptake inhibitors in pregnancy. Curr Drug Saf. 2006, 1 (1): 17-24. 10.2174/157488606775252593.PubMedView Article
- Bellantuono C, Migliarese G, Gentile S: Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. Hum Psychopharmacol. 2007, 22 (3): 121-8. 10.1002/hup.836.PubMedView Article
- Klinger G, Merlob P: Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Isr J Psychiatry Relat Sci. 2008, 45 (2): 107-13.PubMed
- Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G: Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006, 160 (2): 173-6. 10.1001/archpedi.160.2.173.PubMedView Article
- Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM: Use of selective serotonin reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007, 356: 2684-92. 10.1056/NEJMoa066584.PubMedView Article
- Kallen B, Otterblad Olausson P: Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007, 79 (4): 301-8. 10.1002/bdra.20327.PubMedView Article
- Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA: First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007, 356 (26): 2675-83. 10.1056/NEJMoa067407.PubMedView Article
- Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH: Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009, 339: b3569-10.1136/bmj.b3569.PubMed CentralPubMedView Article
- CDER 2004 meeting documents. [http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4050T1.htm]
- Ferreira E, Carceller AM, Agogué C, Martin BZ, St-André M, Francoeur D, Bérard A: Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 2007, 119 (1): 52-9. 10.1542/peds.2006-2133.PubMedView Article
- Laine K, Heikkinen T, Ekblad U, Kero P: Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003, 60 (7): 720-6. 10.1001/archpsyc.60.7.720.PubMedView Article
- Belik J: Fetal and neonatal effects of maternal drug treatment for depression. Semin Perinatol. 2008, 32 (5): 350-4. 10.1053/j.semperi.2008.08.001.PubMedView Article
- Fornaro E, Li D, Pan J, Belik J: Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med. 2007, 176 (10): 1035-40. 10.1164/rccm.200701-163OC.PubMedView Article
- Gentile S, Bellantuono C: Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. J Clin Psychiatry. 2009, 70 (3): 414-22. 10.4088/JCP.08r04468.PubMedView Article
- Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D: First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007, 80: 18-27. 10.1002/bdrb.20099.PubMedView Article
- Gentile S, Rossi A, Bellantuono C: SSRIs during breastfeeding: spotlight on milk-to-plasma ratio. Arch Womens Ment Health. 2007, 10: 39-51. 10.1007/s00737-007-0173-0.PubMedView Article
- Nordeng H, Lindemann R, Perminov KV, Reikvam A: Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001, 90 (3): 288-91. 10.1080/080352501300067596.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.